Get the Stockscreener App
1.90
4.52%
-0.09
After Hours:
1.90
Esperion Therapeutics Inc. stock is currently priced at $1.90, with a 24-hour trading volume of 4.19M.
It has seen a -4.52% decreased in the last 24 hours and a -29.63% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $2.01 pivot point. If it approaches the $1.86 support level, significant changes may occur.
Previous Close:
$1.99
Open:
$2.01
24h Volume:
4.19M
Market Cap:
$359.86M
Revenue:
$116.33M
Net Income/Loss:
$-209.25M
P/E Ratio:
-0.6738
EPS:
-2.82
Net Cash Flow:
$-135.49M
1W Performance:
-2.56%
1M Performance:
-29.63%
6M Performance:
+160.13%
1Y Performance:
+57.02%
1D Range:
$1.88
$2.01
52W Range:
$0.70
$3.40
Esperion Therapeutics Inc. Stock (ESPR) Company Profile
Name
Esperion Therapeutics Inc.
Sector
Phone
734-887-3903
Address
3891 Ranchero Drive, Suite 150, Ann Arbor, MI
Esperion Therapeutics Inc. Stock (ESPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-16-23 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Mar-07-23 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-27-23 | Resumed | BofA Securities | Neutral |
| Feb-24-23 | Upgrade | Jefferies | Hold → Buy |
| Feb-03-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Aug-03-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| May-05-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-10-22 | Initiated | H.C. Wainwright | Buy |
| Oct-19-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| Oct-14-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| May-05-21 | Downgrade | Stifel | Buy → Hold |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-11-21 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-12-21 | Downgrade | Jefferies | Buy → Hold |
| Feb-09-21 | Downgrade | Goldman | Neutral → Sell |
| Jan-15-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-10-20 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-29-20 | Resumed | JP Morgan | Underweight |
| Aug-11-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| Apr-01-20 | Resumed | BofA/Merrill | Buy |
| Mar-17-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-24-20 | Downgrade | Northland Capital | Outperform → Market Perform |
| Feb-14-20 | Downgrade | Citigroup | Buy → Neutral |
| Sep-16-19 | Upgrade | Goldman | Sell → Neutral |
| May-29-19 | Downgrade | Goldman | Neutral → Sell |
| May-06-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Apr-26-19 | Upgrade | Goldman | Sell → Neutral |
| Mar-13-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-07-19 | Reiterated | Needham | Strong Buy |
| Dec-13-18 | Initiated | Goldman | Sell |
| Oct-29-18 | Upgrade | Northland Capital | Market Perform → Outperform |
| Oct-16-18 | Initiated | BTIG Research | Buy |
| Aug-17-18 | Upgrade | Citigroup | Neutral → Buy |
| Jul-11-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-03-18 | Downgrade | JP Morgan | Neutral → Underweight |
| May-02-18 | Downgrade | BofA/Merrill | Buy → Underperform |
View All
Esperion Therapeutics Inc. Stock (ESPR) Latest News
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Zacks Investment Research
Applied Digital Reports Downbeat Results, Joins Nurix Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Benzinga
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Why Esperion Therapeutics Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Benzinga
Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity
GlobeNewswire Inc.
Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
Esperion Therapeutics Inc. Stock (ESPR) Financials Data
Esperion Therapeutics Inc. (ESPR) Revenue 2024
ESPR reported a revenue (TTM) of $116.33 million for the quarter ending December 31, 2023, a +54.14% rise year-over-year.
Esperion Therapeutics Inc. (ESPR) Net Income 2024
ESPR net income (TTM) was -$209.25 million for the quarter ending December 31, 2023, a +10.45% increase year-over-year.
Esperion Therapeutics Inc. (ESPR) Cash Flow 2024
ESPR recorded a free cash flow (TTM) of -$135.49 million for the quarter ending December 31, 2023, a +22.50% increase year-over-year.
Esperion Therapeutics Inc. (ESPR) Earnings per Share 2024
ESPR earnings per share (TTM) was -$2.12 for the quarter ending December 31, 2023, a +40.28% growth year-over-year.
About Esperion Therapeutics Inc.
Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.
1.69%
1.28%
Cap:
|
Volume (24h):